NCT05666349View on ClinicalTrials.gov

Reirradiation and Niraparib in Patients With Recurrent Glioblastoma

PHASE1WithdrawnINTERVENTIONAL
0
Timeline

Start Date

October 13, 2023

Primary Completion Date

October 13, 2023

Study Completion Date

October 13, 2023

Conditions
Recurrent Glioblastoma
Interventions
DRUG

Niraparib

100 mg, 200 mg, or 300mg oral niraparib once daily.

RADIATION

Re-irradiation (re-RT)

Intensity modulated radiotherapy (IMRT)-based re-RT for a total dose of 35 Gy in 10 daily fractions.

Sponsors

Collaborators (1)

GlaxoSmithKline
All Listed Sponsors
collaborator

GlaxoSmithKline

INDUSTRY

lead

University College, London

OTHER

NCT05666349 - Reirradiation and Niraparib in Patients With Recurrent Glioblastoma | Biotech Hunter | Biotech Hunter